A detailed history of Meditor Group LTD transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Meditor Group LTD holds 3,791,300 shares of ESPR stock, worth $8.72 Million. This represents 12.99% of its overall portfolio holdings.

Number of Shares
3,791,300
Previous 3,791,300 -0.0%
Holding current value
$8.72 Million
Previous $8.42 Million 25.68%
% of portfolio
12.99%
Previous 15.57%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 31, 2023

SELL
$0.96 - $1.79 $587,206 - $1.09 Million
-611,673 Reduced 13.89%
3,791,300 $3.72 Million
Q1 2023

Apr 10, 2023

SELL
$1.46 - $7.3 $96,158 - $480,792
-65,862 Reduced 1.47%
4,402,973 $7 Million
Q4 2021

Jan 05, 2022

BUY
$4.81 - $11.92 $7.94 Million - $19.7 Million
1,650,000 Added 58.53%
4,468,835 $22.3 Million
Q2 2021

Jul 12, 2021

BUY
$19.4 - $28.71 $2.7 Million - $3.99 Million
139,000 Added 5.19%
2,818,835 $59.6 Million
Q4 2018

Jan 02, 2019

BUY
$36.99 - $59.11 $1.85 Million - $2.96 Million
50,000 Added 1.9%
2,679,835 $123 Million
Q2 2018

Jul 19, 2018

BUY
$36.2 - $76.4 $1.47 Million - $3.1 Million
40,600 Added 1.57%
2,629,835 $103 Million
Q1 2018

Apr 20, 2018

BUY
$65.94 - $80.76 $17.6 Million - $21.5 Million
266,400 Added 11.47%
2,589,235 $187 Million
Q4 2017

Jan 03, 2018

BUY
$43.47 - $67.43 $1.21 Million - $1.88 Million
27,900 Added 1.22%
2,322,835 $153 Million
Q3 2017

Oct 17, 2017

BUY
$43.8 - $52.77 $101 Million - $121 Million
2,294,935
2,294,935 $115 Million

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $153M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Meditor Group LTD Portfolio

Follow Meditor Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meditor Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Meditor Group LTD with notifications on news.